J&J-Bayer Xarelto’s Use in Prevention Is Effective, FDA Says

Johnson & Johnson and Bayer AG’s blood-thinner Xarelto should be approved to help prevent heart attacks and strokes in patients with a common condition, a U.S. regulatory report recommended.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.